Welcome to our dedicated page for Eli Lilly & Co. news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly & Co. stock.
Eli Lilly and Company (NYSE: LLY), founded in 1876 by Colonel Eli Lilly, is a global leader in the pharmaceutical industry, headquartered in Indianapolis, Indiana. With operations in 18 countries and products sold in approximately 125 countries, Eli Lilly is dedicated to pioneering life-changing discoveries through innovative drug development. The company focuses on several therapeutic areas including neuroscience, cardiometabolic, cancer, and immunology.
Key products in Eli Lilly’s portfolio include Verzenio for cancer treatment; Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes management; and Taltz and Olumiant for immunology. The company's recent financial performance has been robust, with Q1 2024 revenues increasing by 26% year-over-year to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.
Eli Lilly continues to expand its manufacturing capabilities to meet growing demand, recently investing $5.3 billion in its Lebanon, Indiana site. This commitment supports the production of key therapies, particularly for chronic diseases like obesity and type 2 diabetes. The company’s innovative endeavors include the development of new treatments such as the once-weekly insulin efsitora alfa, which showed promising results in phase 3 trials for type 2 diabetes.
The company is also advancing its pipeline of oncology treatments with presentations of data on products like Verzenio, Retevmo, olomorasib, and imlunestrant at major medical conferences. Furthermore, Eli Lilly announced a major leadership change with Melissa Seymour joining as Executive Vice President of Global Quality, ensuring the sustained excellence of their product offerings.
Eli Lilly’s commitment to addressing significant health challenges is evident in its diverse product pipeline and ongoing clinical trials. The company remains focused on improving patient outcomes globally by harnessing advancements in biotechnology, chemistry, and genetic medicine.
The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab for high-risk pediatric patients under 12 years. This allows treatment of mild to moderate COVID-19 and post-exposure prophylaxis. The decision was supported by findings from the BLAZE-1 clinical trial, showing a median symptom resolution time of 5 to 7 days. Over 700,000 patients have been treated, potentially preventing over 35,000 hospitalizations. No deaths or hospitalizations were recorded among pediatric subjects during the trial.
Eli Lilly and Company (NYSE: LLY) will hold an investment community meeting on Dec. 15, 2021, from 9 a.m. to 4 p.m. Eastern time. The meeting will include the company's initial financial guidance for 2022 and an in-depth discussion on its research and development opportunities in diabetes, immunology, neuroscience, and oncology. The event will be accessible via a live video webcast, with a replay available after the meeting.
Eli Lilly and Company (NYSE: LLY) has opened enrollment for the CHALLENGE-MIG clinical trial, the first head-to-head comparison of the anti-CGRP drugs Emgality® (galcanezumab-gnlm) and Nurtec® ODT (rimegepant) for episodic migraine prevention in adults. The trial will assess the efficacy of monthly Emgality injections against bi-daily Nurtec tablets, focusing on migraine days reduction and quality of life. Approximately 700 adults will participate, with results anticipated to guide treatment decisions. The study highlights Lilly's commitment to advancing migraine treatment options.
Eli Lilly and Company (NYSE: LLY) will participate in the fourth annual Evercore ISI HealthCONx Conference on Nov. 30, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, will engage in a fireside chat at 12:10 p.m. Eastern time. A live audio webcast of the event will be available on Lilly's Investor website, with a replay accessible for 90 days post-event.
Lilly, a global healthcare leader, focuses on creating impactful medicines and enhancing disease management.
The FDA has accepted a supplemental New Drug Application for Jardiance (empagliflozin) 10 mg, granting it Priority Review. This application aims to establish Jardiance as a treatment for reducing the risk of cardiovascular death and hospitalization for heart failure in adults, regardless of left ventricular ejection fraction (LVEF). In the EMPEROR-Preserved trial, Jardiance showed a 21% relative risk reduction for the primary endpoint versus placebo. If approved, it would be the first treatment proven to improve outcomes in patients with preserved ejection fraction heart failure.
Eli Lilly and Company (NYSE: LLY) has announced the winners of the inaugural Leonard Award, celebrating the 100th anniversary of insulin's discovery. Each of the five awardees will receive $20,000, totaling $100,000 in donations to Life for a Child, which aids children with type 1 diabetes in low-resource settings. The winners were chosen from over 70 submissions evaluated by an esteemed panel based on impact and feasibility. This initiative highlights Lilly's ongoing commitment to diabetes care and community support.
Eli Lilly and Company (NYSE: LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Nov. 18, 2021. Key executives, including Jacob Van Naarden, CEO of Loxo Oncology, will engage in a fireside chat at 10:30 a.m. Eastern time. Investors can access the event via a live audio webcast on the company's investor website, with a replay available for 90 days afterward. Lilly is committed to improving global health through innovative medicines and community support, continuing a century-old mission.
OLUMIANT (baricitinib) continues to demonstrate a consistent safety profile in a long-term analysis involving 3,770 rheumatoid arthritis (RA) patients across 14,744 patient years of exposure. The overall incidence rate of adverse events stood at 22.6 per 100 patient years, with serious adverse events at 7.4. Safety results will be presented by Eli Lilly and Company and Incyte at ACR Convergence 2021. A real-world study in Japan involving 3,445 RA patients also showed no new safety signals, reinforcing OLUMIANT's safety over 24 weeks. OLUMIANT is approved in over 75 countries for RA treatment.
The EMPEROR-Preserved phase III trial revealed that Jardiance (empagliflozin) significantly reduces the risk of cardiovascular death or hospitalization for heart failure and slows kidney function decline in adults with heart failure and left ventricular ejection fraction (LVEF) over 40%. Presented at the American Society of Nephrology Kidney Week 2021, findings showed consistent benefits regardless of chronic kidney disease (CKD) status. The trial included nearly 6,000 adults, with results highlighting the potential for Jardiance as a viable treatment option. Fast Track and Breakthrough Therapy designations have been granted for its cardiovascular applications.
Loxo Oncology at Lilly announced the upcoming presentation of data from the pirtobrutinib development program at the ASH Annual Meeting, scheduled for December 11-14, 2021. Pirtobrutinib is a reversible BTK inhibitor currently undergoing clinical trials for chronic lymphocytic leukemia and mantle cell lymphoma. Oral presentations will feature updated results from the Phase 1/2 BRUIN trial, focusing on patients previously treated for these conditions. The trials highlight the drug's potential efficacy and innovative mechanism against acquired resistance.
FAQ
What is the current stock price of Eli Lilly & Co. (LLY)?
What is the market cap of Eli Lilly & Co. (LLY)?
What are Eli Lilly's core business areas?
What are some of Eli Lilly's key products?
How did Eli Lilly perform financially in Q1 2024?
What recent investments has Eli Lilly made?
Who is the new Executive Vice President of Global Quality at Eli Lilly?
What are some recent clinical trial results shared by Eli Lilly?
In how many countries does Eli Lilly operate?
What is the significance of Eli Lilly's recent investment in Lebanon, Indiana?
What is the focus of Eli Lilly's ongoing research and development?
What are some common side effects of Eli Lilly's product Mounjaro?
